NCT02604017View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

PHASE3CompletedINTERVENTIONAL

Enrollment

703

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Chronic Hepatitis CHepatitis C VirusHCV

Interventions

DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AbbVie

INDUSTRY